-
Join 34 other subscribers
Categories
Top Posts
Blogroll
Category Archives: Pharmaceutical Industry
Pfizer gives up the chase.
Pfizer is saying today that it does not intend to extend a firm offer for AstraZeneca, bringing an end to its attempt to acquire the UK drug maker. AZ shareholders were split on the latest offer, and a stumble by AZ would … Continue reading
China crackdowns squeeze pharma margins
From Reuters: A crackdown on corruption and pricing in China’s fast-growing pharmaceutical market has squeezed profits and margins, raising a red flag to global Big Pharma that the days of easy growth in the country may be over. Over the … Continue reading
Posted in Pharmaceutical Industry
Tagged branded generics, China, Pharmaceutical industry
Leave a comment
More thoughts on drug company R&D productivity ranking
[updated] Some comments I received on the previous post made me realize there was a more fundamental flaw in drug company R&D productivity rankings that should be highlighted. Drug discovery is by and large a high failure rate multistep process … Continue reading
Who’s The Best In Drug Research? 22 Companies Ranked Incorrectly
Matt Herper at Forbes has a post on new pharmaceutical research productivity data from Richard Evans, a former Roche executive and Wall Street analyst. Evans calculates metrics such as (1) Economic Returns to R&D spending, (2) Patents / $1M R&D spend, (3) Average … Continue reading
Pfizer raises its bid for AstraZeneca – one last time?
Over the weekend, Pfizer finally made an official offer for AstraZeneca, by raising its bid to $119B (15% higher than the last, unofficial, offer), and increasing the cash portion of the deal from 33% to 45%. AZ had a market cap of … Continue reading
Posted in Pharmaceutical Industry
Tagged acquisition, AstraZeneca, megamerger, Pfizer
Leave a comment
Pfizer is a shark that can’t stop feeding
So says John LaMattina, a former head of research at Pfizer: The only way for a shark to survive is to keep going forward. To maintain its leadership, Pfizer will again need to make a major acquisition in the next … Continue reading
Posted in Pharmaceutical Industry
Tagged AstraZeneca, Consolidation, merger, Pfizer, Pharmaceutical industry
Leave a comment
Consolidation in the Pharma industry continues unabated
As large assets swaps, mergers and acquisitions continue in the Pharma industry, Merck has announced it is selling its Consumer Care division to Bayer for $14B. The transaction will move Bayer into second place in consumer care, behind J&J. Merck … Continue reading
Posted in Pharmaceutical Industry
Tagged asset sales, Bayer, Merck, Pharmaceutical industry
Leave a comment
Pfizer won’t take no for an answer
Amidst several indications that Pfizer will launch a hostile bid for AstraZeneca if necessary, this quote stands out: Asked whether hostile moves could hurt integration of the two companies, Chief Executive Ian Read said, “No, in my opinion, all it … Continue reading
Posted in Pharmaceutical Industry
Tagged AstraZeneca, hostile takeover, Ian Read, merger, Pfizer
Leave a comment
Pharma companies consider selling off mature drug portfolios
As big shifts in the Pharmaceutical industry continue, Reuters is reporting that several large pharma companies, including Abbott, Merck and Sanofi, are considering selling off their portfolios of compounds that have lost patent protection. From a pharma company’s perspective, branded … Continue reading
Pfizer’s real strategy is (mostly) tax-minimization
Many observers were initially left scratching their heads over Pfizer’s pursuit of AstraZeneca, a company that has had major pipeline troubles of its own. As more information has come out, Pfizer’s strategy is beginning to make sense. They aren’t pursuing an old-style mega … Continue reading
Posted in Pharmaceutical Industry
Tagged AstraZeneca, merger, Pfizer, Pharma, tax-avoidance
1 Comment
MechanizedIntelligence 